Related Experiment Videos
Tumor reversion: protein kinase A isozyme switching
Yoon S Cho-Chung1, Maria V Nesterova
1Cellular Biochemistry Section, Basic Research Laboratory, National Cancer Institute, Building 10, Room 5B05, 9000 Rockville Pike, Bethesda, MD 20892-1750, USA. yc12b@nih.gov
Annals of the New York Academy of Sciences
|January 6, 2006
Summary
Altering the balance of cAMP-dependent protein kinase (PKA) isozymes, specifically switching between PKA type I and PKA type II, can reverse tumor cell malignancy. This involves regulating genes related to cell growth and differentiation.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- cAMP-dependent protein kinase (PKA) has regulatory subunits RI and RII, defining PKA isozymes type I (PKA-I) and type II (PKA-II).
- The balance between PKA-I and PKA-II is crucial for regulating cell growth and differentiation.
- Imbalance in PKA isozyme expression is implicated in cancer development and progression.
Purpose of the Study:
- To investigate the role of PKA isozyme balance in cancer cell phenotype.
- To determine if manipulating PKA isozyme expression can reverse tumor malignancy.
Main Methods:
- Site-selective cAMP analogs
- Antisense oligonucleotides
- cDNA microarrays
- Gene transfer
- Vector-mediated gene overexpression
Main Results:
- Antisense suppression of RIalpha upregulated RIIbeta, downregulating proliferation and transformation genes while upregulating differentiation genes in prostate tumors.
- Overexpression of RIIbeta, but not RIalpha or Calpha, induced differentiation and suppressed proliferation/transformation genes, leading to tumor phenotype reversion.
- A shift in PKA isozyme balance can trigger phenotypic reversion of malignant tumor cells.
Conclusions:
- The balance of PKA isozymes (RI and RII) is critical for maintaining normal cell growth and differentiation.
- Modulating the expression of PKA isozymes, particularly RIIbeta, offers a potential therapeutic strategy for reversing cancer malignancy.
- Targeting PKA isozyme switching represents a novel approach in cancer therapy for inducing tumor cell differentiation and suppressing proliferation.